Middle East respiratory syndrome vaccines

The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012. No antiviral therapies or vaccines are available for its treatment or prophylaxis. Approaches to the development of MERS v...

Descripción completa

Detalles Bibliográficos
Autores principales: Perlman, Stanley, Vijay, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969153/
https://www.ncbi.nlm.nih.gov/pubmed/27062985
http://dx.doi.org/10.1016/j.ijid.2016.04.008
_version_ 1782445743087288320
author Perlman, Stanley
Vijay, Rahul
author_facet Perlman, Stanley
Vijay, Rahul
author_sort Perlman, Stanley
collection PubMed
description The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012. No antiviral therapies or vaccines are available for its treatment or prophylaxis. Approaches to the development of MERS vaccines are discussed herein, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses. A striking feature of MERS is the important role that camels have in transmission. Camel vaccination may be a novel approach to preventing human infection.
format Online
Article
Text
id pubmed-4969153
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-49691532017-06-01 Middle East respiratory syndrome vaccines Perlman, Stanley Vijay, Rahul Int J Infect Dis Article The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012. No antiviral therapies or vaccines are available for its treatment or prophylaxis. Approaches to the development of MERS vaccines are discussed herein, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses. A striking feature of MERS is the important role that camels have in transmission. Camel vaccination may be a novel approach to preventing human infection. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2016-06 2016-04-07 /pmc/articles/PMC4969153/ /pubmed/27062985 http://dx.doi.org/10.1016/j.ijid.2016.04.008 Text en © 2016 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Perlman, Stanley
Vijay, Rahul
Middle East respiratory syndrome vaccines
title Middle East respiratory syndrome vaccines
title_full Middle East respiratory syndrome vaccines
title_fullStr Middle East respiratory syndrome vaccines
title_full_unstemmed Middle East respiratory syndrome vaccines
title_short Middle East respiratory syndrome vaccines
title_sort middle east respiratory syndrome vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969153/
https://www.ncbi.nlm.nih.gov/pubmed/27062985
http://dx.doi.org/10.1016/j.ijid.2016.04.008
work_keys_str_mv AT perlmanstanley middleeastrespiratorysyndromevaccines
AT vijayrahul middleeastrespiratorysyndromevaccines

Ejemplares similares